3 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
Revenues | $ | - | $ | - | ||||
Operating costs: | ||||||||
General and administrative expenses | 6,499,537 | 2,992,125 | ||||||
Related party travel costs | 453,550 | 1,704,350 | ||||||
Research and development expenses | 1,572,963 | 2,351,465 | ||||||
Total operating costs | 8,526,049 | 7,047,940 | ||||||
Interest expense, net | (3,456,294) | (10,250) | ||||||
Net loss attributable to common stockholders | $ | (11,982,343) | $ | (7,058,190) | ||||
Basic and diluted loss per share | $ | (0.64) | $ | (0.40) | ||||
Weighted average common stock shares outstanding | 18,566,158 | 17,566,533 |
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
2023 | 2022 | |||||||
Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
Revenues | $ | - | $ | - | ||||
Operating costs: | ||||||||
General and administrative expenses | 6,499,537 | 2,992,125 | ||||||
Related party travel costs | 453,550 | 1,704,350 | ||||||
Research and development expenses | 1,572,962 | 2,351,465 | ||||||
Total operating costs | 8,526,049 | 7,047,940 | ||||||
Interest expense, net | (3,456,294) | (10,250) | ||||||
Net loss attributable to common stockholders | $ | (11,982,343) | $ | (7,058,190) | ||||
Basic and diluted loss per share | $ | (0.64) | $ | (0.40) | ||||
Weighted average common stock shares outstanding | 18,566,158 | 17,566,533 |
- Prev
- 1
- Next